Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A primary or metastatic malignant neoplasm involving the small intestine.
Biomarker and diagnostic research for small intestine cancer has been reported in the published literature.
7 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and procedural interventions. Pipeline includes 2 PHASE1, 3 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06715839](https://clinicaltrials.gov/study/NCT06715839) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
Genetic and Rare Diseases Info Center
Target-specific immunoPET Imaging of Digestive System Carcinoma |
NA |
RenJi Hospital |
RECRUITING |
[NCT05038254](https://clinicaltrials.gov/study/NCT05038254) | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | NA | M.D. Anderson Cancer Center | ACTIVE_NOT_RECRUITING |
[NCT07060014](https://clinicaltrials.gov/study/NCT07060014) | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers | PHASE1 | The Methodist Hospital Research Institute | NOT_YET_RECRUITING |
[NCT04907643](https://clinicaltrials.gov/study/NCT04907643) | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NA | Cedars-Sinai Medical Center | RECRUITING |
[NCT05592626](https://clinicaltrials.gov/study/NCT05592626) | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | PHASE1 | Marengo Therapeutics, Inc. | RECRUITING |
198 publications have been identified in PubMed for small intestine cancer. Research spans Basic Science / Preclinical (27%), Epidemiology / Natural History (19%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 53 | 27% |
Disease patterns and progression | 38 | 19% |
Research summaries | 30 | 15% |
Patient case studies | 28 | 14% |
Clinical study results | 24 | 12% |
Testing and diagnosis research | 18 | 9% |
New treatment approaches | 5 | 3% |
Other research | 2 | 1% |
Lee Y (2026). [PMID: 41251953](https://pubmed.ncbi.nlm.nih.gov/41251953/). *Dig Endosc*. [Clinical Trial Publication]
Lamarca A (2026). [PMID: 41392200](https://pubmed.ncbi.nlm.nih.gov/41392200/). *Oncologist*. [Clinical Trial Publication]
Yogo A (2026). [PMID: 41886547](https://pubmed.ncbi.nlm.nih.gov/41886547/). *Endocr Relat Cancer*. [Case Report / Case Series]
Endo R (2026). [PMID: 41468887](https://pubmed.ncbi.nlm.nih.gov/41468887/). *Cell Stem Cell*. [Basic Science / Preclinical]
Tsuboi A (2026). [PMID: 41251800](https://pubmed.ncbi.nlm.nih.gov/41251800/). *J Gastroenterol*. [Epidemiology / Natural History]
Helgadottir SD (2026). [PMID: 42201789](https://pubmed.ncbi.nlm.nih.gov/42201789/). *Laeknabladid*. [Epidemiology / Natural History]
Kitamura M (2026). [PMID: 41699266](https://pubmed.ncbi.nlm.nih.gov/41699266/). *J Gastroenterol*. [Epidemiology / Natural History]
Yasinzai AQK (2026). [PMID: 41104650](https://pubmed.ncbi.nlm.nih.gov/41104650/). *Journal of the National Cancer Institute*. [Epidemiology / Natural History]
Kuribara H (2026). [PMID: 41360618](https://pubmed.ncbi.nlm.nih.gov/41360618/). *Dig Endosc*. [Case Report / Case Series]
Dalmeijer SWR (2026). [PMID: 42150271](https://pubmed.ncbi.nlm.nih.gov/42150271/). *Surg Oncol*. [Diagnostic / Biomarker]